Nalaganje...
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib
BACKGROUND: Sorafenib, a multi-target kinase inhibitor, inhibits members of the MAPK pathway and receptor tyrosine kinases, including VEGF-R2. Sorafenib, carboplatin and paclitaxel (SCP) has anti-tumor activity in melanoma patients, but no association was found between response and activating B-Raf(...
Shranjeno v:
| izdano v: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2009
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4263281/ https://ncbi.nlm.nih.gov/pubmed/19188183 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2280 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|